The global market for human leukocyte antigen (HLA) typing is entering a transformative growth phase, driven by technological innovation, rising organ transplant procedures, and increasing awareness of organ donation. Valued at US $1.6 billion in 2024, the market rose to US $1.7 billion in 2025 and is forecasted to expand at a CAGR of 6.0%, reaching US $2.3 billion by 2030. This upward trajectory highlights how crucial accurate HLA typing has become for successful transplantation and precision diagnostics worldwide.

Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=39129877

Why HLA Typing Matters More Than Ever

HLA typing plays a vital role in determining compatibility between donors and recipients during organ and stem cell transplantation. By ensuring genetic matching at the HLA level, healthcare providers can minimize the risk of graft rejection and improve long-term transplant outcomes. It also helps prevent severe complications like graft-versus-host disease (GVHD) and post-transplant lymphoproliferative disorders.

With a rising global burden of chronic diseases such as renal failure, liver cirrhosis, and hematologic malignancies, the demand for transplantation has surged. In 2024 alone, the United Network for Organ Sharing (UNOS) reported a record 48,149 organ transplants performed in the United States—averaging 132 transplants per day. These growing procedural volumes translate directly into higher demand for reliable and efficient HLA typing technologies.

Key Market Drivers: Transplants, Technology, and Awareness

1. Rising Number of Transplant Surgeries

A growing geriatric population, increasing prevalence of chronic conditions, and improved surgical outcomes are pushing transplantation into mainstream medical practice. More patients are now eligible for transplants than ever before. As healthcare systems expand transplant capacity, they also need better diagnostics—putting HLA typing at the center of pre-transplant evaluations.

2. Technological Breakthroughs

Technological innovation is accelerating the speed, accuracy, and scalability of HLA typing. Molecular techniques such as PCR (polymerase chain reaction) and NGS (next-generation sequencing) are enabling high-resolution genotyping with unprecedented precision. New product launches, like Omixon’s NanoTYPE kits and Roche’s next-generation qPCR systems, are streamlining workflows and improving turnaround times in clinical laboratories.

3. Awareness and Organ Donation Initiatives

Governments, NGOs, and healthcare organizations are investing heavily in organ donation awareness campaigns to close the gap between demand and supply. International efforts, such as global awareness drives held in August 2024, are encouraging more individuals to register as organ donors. As donation rates rise, so too does the need for rapid and reliable donor-recipient matching.

Market Restraints: High Costs and Reimbursement Gaps

Despite these positive developments, the HLA typing market faces notable challenges. One major barrier is inadequate reimbursement for transplant diagnostics and procedures in many regions. In countries like the United States, reimbursement for HLA typing is limited to specific cases, such as pre-kidney transplant evaluations or complex transfusion scenarios.

Moreover, in developing regions across Asia-Pacific, the Middle East, and Africa, the lack of comprehensive reimbursement frameworks makes advanced diagnostics inaccessible to a large segment of the population. This cost factor can slow the adoption of cutting-edge molecular testing methods, particularly for healthcare providers working with constrained budgets.

Another challenge is the shortage of trained personnel to operate advanced HLA typing technologies. High-resolution sequencing platforms require skilled bioinformaticians to interpret data accurately. However, with only around 15,000 bioinformatics professionals supporting over 2 million life science researchers globally, this shortage poses a bottleneck to market scalability.

Opportunities Ahead: Bridging the Organ Gap

The growing awareness of organ donation presents a powerful opportunity for market expansion. Countries like Japan, Germany, the UK, China, and India are witnessing a rising number of patients joining transplant waiting lists. This growing demand highlights the importance of improving organ availability through public campaigns, donor registries, and policy support.

In parallel, innovations in software and automation are making HLA typing more accessible and easier to integrate into clinical workflows. AI-powered bioinformatics platforms can streamline data analysis, reducing dependency on specialized personnel and enabling faster, more accurate matching.

Market Segmentation and Ecosystem Overview

The HLA typing market is structured around three key product segments:

• Reagents and consumables – accounting for the largest share, driven by the need for frequent testing and replenishment.
• Instruments – including advanced sequencing platforms and PCR systems.
• Software and services – essential for data analysis and reporting.

On the end-user side, commercial service providers lead the market, leveraging high-throughput platforms to offer fast, precise, and scalable testing. Hospitals, transplant centers, and research laboratories follow closely, adopting these technologies to improve patient outcomes.

Regional Insights: North America Leads the Way

North America remains the largest and most mature market for HLA typing. A well-established healthcare infrastructure, robust transplant registries such as the National Marrow Donor Program (NMDP), and government funding for transplant research support market dominance.

The region’s high prevalence of chronic diseases and emphasis on personalized medicine further drive adoption. Technological advancements, combined with the presence of leading market players, have positioned North America as a global hub for HLA testing innovation.

The United States stands out as the fastest-growing market in the region, with a CAGR of 7.5%. Meanwhile, Canada’s market faces cost-related challenges, particularly around PCR and NGS software.

Industry Developments and Competitive Landscape

The HLA typing landscape is characterized by intense innovation and strategic partnerships. Some notable developments include:

• November 2023: F. Hoffmann-La Roche Ltd launched a next-generation qPCR system to enhance clinical diagnostics.
• October 2023: Gendx introduced the NGS-Turbo, a high-resolution typing kit compatible with Oxford Nanopore sequencing devices.
• September 2023: Omixon unveiled the NanoTYPE MONO and MONOall kits for single-locus HLA typing.
• October 2023: Eurobio Scientific acquired Genome Diagnostics BV (GenDx), further expanding its molecular diagnostics portfolio.

Key market players shaping this landscape include Becton, Dickinson and Company, Thermo Fisher Scientific Inc., Bio-Rad Laboratories, Inc., Bruker, Caredx, Inc., Illumina, Inc., and others.

Looking Ahead: A Future of Precision and Equity

The global HLA typing market stands at the intersection of personalized medicine, transplant innovation, and global health equity. As governments, healthcare systems, and industry leaders work to make organ transplantation more accessible, the role of HLA typing will only grow in importance. Future growth will be fueled by AI integration, automation of laboratory workflows, increased donor registration, and continued technological breakthroughs. By 2030, the market’s projected size of US $2.3 billion underscores its pivotal role in improving patient outcomes, saving lives, and advancing the promise of precision medicine.